Zacks Research Forecasts Perrigo’s Q1 Earnings (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) – Investment analysts at Zacks Research decreased their Q1 2027 earnings estimates for Perrigo in a research note issued to investors on Monday, March 23rd. Zacks Research analyst Team now forecasts that the company will earn $0.68 per share for the quarter, down from their previous forecast of $0.69. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2027 earnings at $0.54 EPS, FY2027 earnings at $2.51 EPS and FY2028 earnings at $2.57 EPS.

A number of other equities research analysts have also recently weighed in on PRGO. Argus upgraded Perrigo to a “hold” rating in a research note on Wednesday, January 14th. Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. JPMorgan Chase & Co. reduced their price target on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Canaccord Genuity Group decreased their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $19.33.

Perrigo Trading Up 0.5%

NYSE:PRGO opened at $9.69 on Tuesday. The company has a market capitalization of $1.33 billion, a PE ratio of -0.94, a P/E/G ratio of 1.14 and a beta of 0.41. Perrigo has a 52-week low of $9.23 and a 52-week high of $28.43. The stock’s 50 day moving average price is $12.97 and its 200 day moving average price is $15.78. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, February 26th. The company reported $0.77 EPS for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the firm posted $0.93 EPS. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 24th. Shareholders of record on Monday, March 2nd were given a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 12.0%. The ex-dividend date of this dividend was Monday, March 2nd. Perrigo’s dividend payout ratio (DPR) is presently -11.28%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Amundi raised its stake in shares of Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after purchasing an additional 556 shares during the last quarter. Slocum Gordon & Co LLP grew its position in Perrigo by 1.1% in the 3rd quarter. Slocum Gordon & Co LLP now owns 53,253 shares of the company’s stock valued at $1,186,000 after buying an additional 602 shares during the last quarter. Kestra Investment Management LLC increased its stake in Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after buying an additional 642 shares during the period. State of Wyoming increased its stake in Perrigo by 7.8% in the 3rd quarter. State of Wyoming now owns 8,988 shares of the company’s stock valued at $200,000 after buying an additional 653 shares during the period. Finally, First Citizens Bank & Trust Co. raised its position in Perrigo by 4.7% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 17,323 shares of the company’s stock worth $386,000 after buying an additional 775 shares during the last quarter. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.